Anhui’s Anke Biotechnology Co. has already licensed KGF-2 (lyophilized recombinant human keratinocyte growth factor-2). The licensing of aFGF is to develop technology for diabetic foot treatment. China has 114 million diabetic patients, over 30% of all patients have skin lesions, one of the most typical and most harmful symptoms of diabetic foot. 3% to 6% of diabetic patients have foot ulcers, and 70% of patients require surgery. Amputation rate of diabetics is > 10 %

China Bio news release, Nov. 26, 2014